Heart Failure Drugs Industry Research Report 2023

Heart Failure Drugs Industry Research Report 2023


Heart failure occurs when your heart muscle doesn't pump blood as well as it should.

Highlights

The global Heart Failure Drugs market is projected to reach US$ million by 2029 from an estimated US$ million in 2023, at a CAGR of % during 2024 and 2029.
The market is concentrated as Novartis, Pfizer, AstraZeneca , Hikma, Teva etc. Turkey is the largest consumption place in the Turkey and Middle East & Africa market, with a consumption market share nearly 21%.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Heart Failure Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Heart Failure Drugs.
The Heart Failure Drugs market size, estimations, and forecasts are provided in terms of sales volume (MT) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Heart Failure Drugs market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Heart Failure Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights


In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2018-2023. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Novartis
Pfizer
AstraZeneca
Hikma
Teva
Cipla
Merck & Co.
Amgen
Roche
Sun Pharma
Mylan

Product Type Insights

Global markets are presented by Heart Failure Drugs type, along with growth forecasts through 2029. Estimates on sales and revenue are based on the price in the supply chain at which the Heart Failure Drugs are procured by the manufacturers.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).
Heart Failure Drugs segment by Type

ACEI
Angiotensin II Receptor Blockers
ARNIs
Beta Blockers
Aldosterone Antagonists
Diuretics

Application Insights

This report has provided the market size (sales and revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).
This report also outlines the market trends of each segment and consumer behaviors impacting the Heart Failure Drugs market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Heart Failure Drugs market.
Heart Failure Drugs segment by Application

Reduced Ejection Fraction
Preserved Ejection Fraction

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2018-2029.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2023 and forecast revenue for 2029.

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Heart Failure Drugs market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Heart Failure Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Heart Failure Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Heart Failure Drugs industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Heart Failure Drugs.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Heart Failure Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Heart Failure Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Heart Failure Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Frequently Asked Questions

Which product segment grabbed the largest share in the Product Name market?
How is the competitive scenario of the Product Name market?
Which are the key factors aiding the Product Name market growth?
Which are the prominent players in the Product Name market?
Which region holds the maximum share in the Product Name market?
What will be the CAGR of the Product Name market during the forecast period?
Which application segment emerged as the leading segment in the Product Name market?
What key trends are likely to emerge in the Product Name market in the coming years?
What will be the Product Name market size by 2028?
Which company held the largest share in the Product Name market?


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Heart Failure Drugs Market Size (2018-2029) & (US$ Million)
2.2.2 Global Heart Failure Drugs Sales (2018-2029)
2.2.3 Global Heart Failure Drugs Market Average Price (2018-2029)
2.3 Heart Failure Drugs by Type
2.3.1 Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US$ Million)
1.2.2 ACEI
1.2.3 Angiotensin II Receptor Blockers
1.2.4 ARNIs
1.2.5 Beta Blockers
1.2.6 Aldosterone Antagonists
1.2.7 Diuretics
2.4 Heart Failure Drugs by Application
2.4.1 Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US$ Million)
2.4.2 Reduced Ejection Fraction
2.4.3 Preserved Ejection Fraction
3 Market Competitive Landscape by Manufacturers
3.1 Global Heart Failure Drugs Market Competitive Situation by Manufacturers (2018 Versus 2022)
3.2 Global Heart Failure Drugs Sales (MT) of Manufacturers (2018-2023)
3.3 Global Heart Failure Drugs Revenue of Manufacturers (2018-2023)
3.4 Global Heart Failure Drugs Average Price by Manufacturers (2018-2023)
3.5 Global Heart Failure Drugs Industry Ranking, 2021 VS 2022 VS 2023
3.6 Global Manufacturers of Heart Failure Drugs, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Heart Failure Drugs, Product Type & Application
3.8 Global Manufacturers of Heart Failure Drugs, Date of Enter into This Industry
3.9 Global Heart Failure Drugs Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Novartis
4.1.1 Novartis Company Information
4.1.2 Novartis Business Overview
4.1.3 Novartis Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
4.1.4 Novartis Heart Failure Drugs Product Portfolio
4.1.5 Novartis Recent Developments
4.2 Pfizer
4.2.1 Pfizer Company Information
4.2.2 Pfizer Business Overview
4.2.3 Pfizer Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
4.2.4 Pfizer Heart Failure Drugs Product Portfolio
4.2.5 Pfizer Recent Developments
4.3 AstraZeneca
4.3.1 AstraZeneca Company Information
4.3.2 AstraZeneca Business Overview
4.3.3 AstraZeneca Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
4.3.4 AstraZeneca Heart Failure Drugs Product Portfolio
4.3.5 AstraZeneca Recent Developments
4.4 Hikma
4.4.1 Hikma Company Information
4.4.2 Hikma Business Overview
4.4.3 Hikma Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
4.4.4 Hikma Heart Failure Drugs Product Portfolio
4.4.5 Hikma Recent Developments
4.5 Teva
4.5.1 Teva Company Information
4.5.2 Teva Business Overview
4.5.3 Teva Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Teva Heart Failure Drugs Product Portfolio
6.5.5 Teva Recent Developments
4.6 Cipla
4.6.1 Cipla Company Information
4.6.2 Cipla Business Overview
4.6.3 Cipla Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
4.6.4 Cipla Heart Failure Drugs Product Portfolio
4.6.5 Cipla Recent Developments
4.7 Merck & Co.
4.7.1 Merck & Co. Company Information
4.7.2 Merck & Co. Business Overview
4.7.3 Merck & Co. Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
4.7.4 Merck & Co. Heart Failure Drugs Product Portfolio
4.7.5 Merck & Co. Recent Developments
6.8 Amgen
4.8.1 Amgen Company Information
4.8.2 Amgen Business Overview
4.8.3 Amgen Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
4.8.4 Amgen Heart Failure Drugs Product Portfolio
4.8.5 Amgen Recent Developments
4.9 Roche
4.9.1 Roche Company Information
4.9.2 Roche Business Overview
4.9.3 Roche Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
4.9.4 Roche Heart Failure Drugs Product Portfolio
4.9.5 Roche Recent Developments
4.10 Sun Pharma
4.10.1 Sun Pharma Company Information
4.10.2 Sun Pharma Business Overview
4.10.3 Sun Pharma Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
4.10.4 Sun Pharma Heart Failure Drugs Product Portfolio
4.10.5 Sun Pharma Recent Developments
6.11 Mylan
6.11.1 Mylan Company Information
6.11.2 Mylan Heart Failure Drugs Business Overview
6.11.3 Mylan Heart Failure Drugs Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Mylan Heart Failure Drugs Product Portfolio
6.11.5 Mylan Recent Developments
5 Global Heart Failure Drugs Market Scenario by Region
5.1 Global Heart Failure Drugs Market Size by Region: 2018 VS 2022 VS 2029
5.2 Global Heart Failure Drugs Sales by Region: 2018-2029
5.2.1 Global Heart Failure Drugs Sales by Region: 2018-2023
5.2.2 Global Heart Failure Drugs Sales by Region: 2024-2029
5.3 Global Heart Failure Drugs Revenue by Region: 2018-2029
5.3.1 Global Heart Failure Drugs Revenue by Region: 2018-2023
5.3.2 Global Heart Failure Drugs Revenue by Region: 2024-2029
5.4 North America Heart Failure Drugs Market Facts & Figures by Country
5.4.1 North America Heart Failure Drugs Market Size by Country: 2018 VS 2022 VS 2029
5.4.2 North America Heart Failure Drugs Sales by Country (2018-2029)
5.4.3 North America Heart Failure Drugs Revenue by Country (2018-2029)
5.4.4 U.S.
5.4.5 Canada
5.5 Europe Heart Failure Drugs Market Facts & Figures by Country
5.5.1 Europe Heart Failure Drugs Market Size by Country: 2018 VS 2022 VS 2029
5.5.2 Europe Heart Failure Drugs Sales by Country (2018-2029)
5.5.3 Europe Heart Failure Drugs Revenue by Country (2018-2029)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.6 Asia Pacific Heart Failure Drugs Market Facts & Figures by Country
5.6.1 Asia Pacific Heart Failure Drugs Market Size by Country: 2018 VS 2022 VS 2029
5.6.2 Asia Pacific Heart Failure Drugs Sales by Country (2018-2029)
5.6.3 Asia Pacific Heart Failure Drugs Revenue by Country (2018-2029)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Indonesia
5.6.11 Thailand
5.6.12 Malaysia
5.7 Latin America Heart Failure Drugs Market Facts & Figures by Country
5.7.1 Latin America Heart Failure Drugs Market Size by Country: 2018 VS 2022 VS 2029
5.7.2 Latin America Heart Failure Drugs Sales by Country (2018-2029)
5.7.3 Latin America Heart Failure Drugs Revenue by Country (2018-2029)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa Heart Failure Drugs Market Facts & Figures by Country
5.8.1 Middle East and Africa Heart Failure Drugs Market Size by Country: 2018 VS 2022 VS 2029
5.8.2 Middle East and Africa Heart Failure Drugs Sales by Country (2018-2029)
5.8.3 Middle East and Africa Heart Failure Drugs Revenue by Country (2018-2029)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global Heart Failure Drugs Sales by Type (2018-2029)
6.1.1 Global Heart Failure Drugs Sales by Type (2018-2029) & (MT)
6.1.2 Global Heart Failure Drugs Sales Market Share by Type (2018-2029)
6.2 Global Heart Failure Drugs Revenue by Type (2018-2029)
6.2.1 Global Heart Failure Drugs Sales by Type (2018-2029) & (US$ Million)
6.2.2 Global Heart Failure Drugs Revenue Market Share by Type (2018-2029)
6.3 Global Heart Failure Drugs Price by Type (2018-2029)
7 Segment by Application
7.1 Global Heart Failure Drugs Sales by Application (2018-2029)
7.1.1 Global Heart Failure Drugs Sales by Application (2018-2029) & (MT)
7.1.2 Global Heart Failure Drugs Sales Market Share by Application (2018-2029)
7.2 Global Heart Failure Drugs Revenue by Application (2018-2029)
6.2.1 Global Heart Failure Drugs Sales by Application (2018-2029) & (US$ Million)
6.2.2 Global Heart Failure Drugs Revenue Market Share by Application (2018-2029)
7.3 Global Heart Failure Drugs Price by Application (2018-2029)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Heart Failure Drugs Value Chain Analysis
8.1.1 Heart Failure Drugs Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Heart Failure Drugs Production Mode & Process
8.2 Heart Failure Drugs Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Heart Failure Drugs Distributors
8.2.3 Heart Failure Drugs Customers
9 Global Heart Failure Drugs Analyzing Market Dynamics
9.1 Heart Failure Drugs Industry Trends
9.2 Heart Failure Drugs Industry Drivers
9.3 Heart Failure Drugs Industry Opportunities and Challenges
9.4 Heart Failure Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US$ Million)
Table 4. Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US$ Million)
Table 5. Global Heart Failure Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2018 Versus 2022)
Table 6. Global Heart Failure Drugs Sales (MT) of Manufacturers (2018-2023)
Table 7. Global Heart Failure Drugs Sales Market Share by Manufacturers (2018-2023)
Table 8. Global Heart Failure Drugs Revenue of Manufacturers (2018-2023)
Table 9. Global Heart Failure Drugs Revenue Share by Manufacturers (2018-2023)
Table 10. Global Market Heart Failure Drugs Average Price (USD/MT) of Manufacturers (2018-2023)
Table 11. Global Heart Failure Drugs Industry Ranking, 2021 VS 2022 VS 2023
Table 12. Global Manufacturers of Heart Failure Drugs, Product Type & Application
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Heart Failure Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 16. Novartis Company Information
Table 17. Novartis Business Overview
Table 18. Novartis Heart Failure Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 19. Novartis Heart Failure Drugs Product Portfolio
Table 20. Novartis Recent Developments
Table 21. Pfizer Company Information
Table 22. Pfizer Business Overview
Table 23. Pfizer Heart Failure Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 24. Pfizer Heart Failure Drugs Product Portfolio
Table 25. Pfizer Recent Developments
Table 26. AstraZeneca Company Information
Table 27. AstraZeneca Business Overview
Table 28. AstraZeneca Heart Failure Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 29. AstraZeneca Heart Failure Drugs Product Portfolio
Table 30. AstraZeneca Recent Developments
Table 31. Hikma Company Information
Table 32. Hikma Business Overview
Table 33. Hikma Heart Failure Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 34. Hikma Heart Failure Drugs Product Portfolio
Table 35. Hikma Recent Developments
Table 36. Teva Company Information
Table 37. Teva Business Overview
Table 38. Teva Heart Failure Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 39. Teva Heart Failure Drugs Product Portfolio
Table 40. Teva Recent Developments
Table 41. Cipla Company Information
Table 42. Cipla Business Overview
Table 43. Cipla Heart Failure Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 44. Cipla Heart Failure Drugs Product Portfolio
Table 45. Cipla Recent Developments
Table 46. Merck & Co. Company Information
Table 47. Merck & Co. Business Overview
Table 48. Merck & Co. Heart Failure Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 49. Merck & Co. Heart Failure Drugs Product Portfolio
Table 50. Merck & Co. Recent Developments
Table 51. Amgen Company Information
Table 52. Amgen Business Overview
Table 53. Amgen Heart Failure Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 54. Amgen Heart Failure Drugs Product Portfolio
Table 55. Amgen Recent Developments
Table 56. Roche Company Information
Table 57. Roche Business Overview
Table 58. Roche Heart Failure Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 59. Roche Heart Failure Drugs Product Portfolio
Table 60. Roche Recent Developments
Table 61. Sun Pharma Company Information
Table 62. Sun Pharma Business Overview
Table 63. Sun Pharma Heart Failure Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 64. Sun Pharma Heart Failure Drugs Product Portfolio
Table 65. Sun Pharma Recent Developments
Table 66. Mylan Company Information
Table 67. Mylan Business Overview
Table 68. Mylan Heart Failure Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 69. Mylan Heart Failure Drugs Product Portfolio
Table 70. Mylan Recent Developments
Table 71. Global Heart Failure Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 72. Global Heart Failure Drugs Sales by Region (2018-2023) & (MT)
Table 73. Global Heart Failure Drugs Sales Market Share by Region (2018-2023)
Table 74. Global Heart Failure Drugs Sales by Region (2024-2029) & (MT)
Table 75. Global Heart Failure Drugs Sales Market Share by Region (2024-2029)
Table 76. Global Heart Failure Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 77. Global Heart Failure Drugs Revenue Market Share by Region (2018-2023)
Table 78. Global Heart Failure Drugs Revenue by Region (2024-2029) & (US$ Million)
Table 79. Global Heart Failure Drugs Revenue Market Share by Region (2024-2029)
Table 80. North America Heart Failure Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 81. North America Heart Failure Drugs Sales by Country (2018-2023) & (MT)
Table 82. North America Heart Failure Drugs Sales by Country (2024-2029) & (MT)
Table 83. North America Heart Failure Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 84. North America Heart Failure Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 85. Europe Heart Failure Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 86. Europe Heart Failure Drugs Sales by Country (2018-2023) & (MT)
Table 87. Europe Heart Failure Drugs Sales by Country (2024-2029) & (MT)
Table 88. Europe Heart Failure Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 89. Europe Heart Failure Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 90. Asia Pacific Heart Failure Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 91. Asia Pacific Heart Failure Drugs Sales by Country (2018-2023) & (MT)
Table 92. Asia Pacific Heart Failure Drugs Sales by Country (2024-2029) & (MT)
Table 93. Asia Pacific Heart Failure Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 94. Asia Pacific Heart Failure Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 95. Latin America Heart Failure Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 96. Latin America Heart Failure Drugs Sales by Country (2018-2023) & (MT)
Table 97. Latin America Heart Failure Drugs Sales by Country (2024-2029) & (MT)
Table 98. Latin America Heart Failure Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 99. Latin America Heart Failure Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 100. Middle East and Africa Heart Failure Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 101. Middle East and Africa Heart Failure Drugs Sales by Country (2018-2023) & (MT)
Table 102. Middle East and Africa Heart Failure Drugs Sales by Country (2024-2029) & (MT)
Table 103. Middle East and Africa Heart Failure Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 104. Middle East and Africa Heart Failure Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 105. Global Heart Failure Drugs Sales by Type (2018-2023) & (MT)
Table 106. Global Heart Failure Drugs Sales by Type (2024-2029) & (MT)
Table 107. Global Heart Failure Drugs Sales Market Share by Type (2018-2023)
Table 108. Global Heart Failure Drugs Sales Market Share by Type (2024-2029)
Table 109. Global Heart Failure Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 110. Global Heart Failure Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 111. Global Heart Failure Drugs Revenue Market Share by Type (2018-2023)
Table 112. Global Heart Failure Drugs Revenue Market Share by Type (2024-2029)
Table 113. Global Heart Failure Drugs Price by Type (2018-2023) & (USD/MT)
Table 114. Global Heart Failure Drugs Price by Type (2024-2029) & (USD/MT)
Table 115. Global Heart Failure Drugs Sales by Application (2018-2023) & (MT)
Table 116. Global Heart Failure Drugs Sales by Application (2024-2029) & (MT)
Table 117. Global Heart Failure Drugs Sales Market Share by Application (2018-2023)
Table 118. Global Heart Failure Drugs Sales Market Share by Application (2024-2029)
Table 119. Global Heart Failure Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 120. Global Heart Failure Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 121. Global Heart Failure Drugs Revenue Market Share by Application (2018-2023)
Table 122. Global Heart Failure Drugs Revenue Market Share by Application (2024-2029)
Table 123. Global Heart Failure Drugs Price by Application (2018-2023) & (USD/MT)
Table 124. Global Heart Failure Drugs Price by Application (2024-2029) & (USD/MT)
Table 125. Key Raw Materials
Table 126. Raw Materials Key Suppliers
Table 127. Heart Failure Drugs Distributors List
Table 128. Heart Failure Drugs Customers List
Table 129. Heart Failure Drugs Industry Trends
Table 130. Heart Failure Drugs Industry Drivers
Table 131. Heart Failure Drugs Industry Restraints
Table 132. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Heart Failure DrugsProduct Picture
Figure 5. Global Heart Failure Drugs Revenue (US$ Million), 2018 VS 2022 VS 2029
Figure 6. Global Heart Failure Drugs Market Size (2018-2029) & (US$ Million)
Figure 7. Global Heart Failure Drugs Sales (2018-2029) & (MT)
Figure 8. Global Heart Failure Drugs Average Price (USD/MT) & (2018-2029)
Figure 9. ACEI Product Picture
Figure 10. Angiotensin II Receptor Blockers Product Picture
Figure 11. ARNIs Product Picture
Figure 12. Beta Blockers Product Picture
Figure 13. Aldosterone Antagonists Product Picture
Figure 14. Diuretics Product Picture
Figure 15. Reduced Ejection Fraction Product Picture
Figure 16. Preserved Ejection Fraction Product Picture
Figure 17. Global Heart Failure Drugs Revenue Share by Manufacturers in 2022
Figure 18. Global Manufacturers of Heart Failure Drugs, Manufacturing Sites & Headquarters
Figure 19. Global Manufacturers of Heart Failure Drugs, Date of Enter into This Industry
Figure 20. Global Top 5 and 10 Heart Failure Drugs Players Market Share by Revenue in 2022
Figure 21. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 22. Global Heart Failure Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 23. Global Heart Failure Drugs Sales by Region in 2022
Figure 24. Global Heart Failure Drugs Revenue by Region in 2022
Figure 25. North America Heart Failure Drugs Market Size by Country in 2022
Figure 26. North America Heart Failure Drugs Sales Market Share by Country (2018-2029)
Figure 27. North America Heart Failure Drugs Revenue Market Share by Country (2018-2029)
Figure 28. U.S. Heart Failure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. Canada Heart Failure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. Europe Heart Failure Drugs Market Size by Country in 2022
Figure 31. Europe Heart Failure Drugs Sales Market Share by Country (2018-2029)
Figure 32. Europe Heart Failure Drugs Revenue Market Share by Country (2018-2029)
Figure 33. Germany Heart Failure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. France Heart Failure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. U.K. Heart Failure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Italy Heart Failure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. Russia Heart Failure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. Asia Pacific Heart Failure Drugs Market Size by Country in 2022
Figure 39. Asia Pacific Heart Failure Drugs Sales Market Share by Country (2018-2029)
Figure 40. Asia Pacific Heart Failure Drugs Revenue Market Share by Country (2018-2029)
Figure 41. China Heart Failure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Japan Heart Failure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. South Korea Heart Failure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. India Heart Failure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Australia Heart Failure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. China Taiwan Heart Failure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Indonesia Heart Failure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Thailand Heart Failure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Malaysia Heart Failure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Latin America Heart Failure Drugs Market Size by Country in 2022
Figure 51. Latin America Heart Failure Drugs Sales Market Share by Country (2018-2029)
Figure 52. Latin America Heart Failure Drugs Revenue Market Share by Country (2018-2029)
Figure 53. Mexico Heart Failure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Brazil Heart Failure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 55. Argentina Heart Failure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 56. Middle East and Africa Heart Failure Drugs Market Size by Country in 2022
Figure 57. Middle East and Africa Heart Failure Drugs Sales Market Share by Country (2018-2029)
Figure 58. Middle East and Africa Heart Failure Drugs Revenue Market Share by Country (2018-2029)
Figure 59. Turkey Heart Failure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 60. Saudi Arabia Heart Failure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 61. UAE Heart Failure Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 62. Global Heart Failure Drugs Sales Market Share by Type (2018-2029)
Figure 63. Global Heart Failure Drugs Revenue Market Share by Type (2018-2029)
Figure 64. Global Heart Failure Drugs Price (USD/MT) by Type (2018-2029)
Figure 65. Global Heart Failure Drugs Sales Market Share by Application (2018-2029)
Figure 66. Global Heart Failure Drugs Revenue Market Share by Application (2018-2029)
Figure 67. Global Heart Failure Drugs Price (USD/MT) by Application (2018-2029)
Figure 68. Heart Failure Drugs Value Chain
Figure 69. Heart Failure Drugs Production Mode & Process
Figure 70. Direct Comparison with Distribution Share
Figure 71. Distributors Profiles
Figure 72. Heart Failure Drugs Industry Opportunities and Challenges

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings